Movement Alert｜Moderna, Inc. Surges 85.9% in Regular Trading, Phase III mRNA Cancer Vaccine Trial Achieves Primary Endpoint

Market Focus

Aug 19

On August 19, Moderna, Inc. surged 85.9% in regular trading, trading at $115.505/share, with turnover of $2.791 billion.

The surge was driven by Moderna and Merck jointly announcing that their pivotal Phase III clinical trial Interpath-001 achieved positive results. The trial evaluated intismeran autogene, a personalized neoantigen therapy, in combination with Keytruda for patients with completely resected stage IIB-IV melanoma. The combination demonstrated statistically significant and clinically meaningful improvements in both recurrence-free survival and distant metastasis-free survival compared with Keytruda alone, with no new safety signals identified.

This marks the first Phase III trial success for mRNA technology in oncology, representing a major milestone for personalized immunotherapy. The two companies stated they plan to engage regulatory authorities regarding submission of the combination therapy. William Blair subsequently upgraded Moderna to Outperform. Merck shares rose over 7%, while sector peer BioNTech gained 18.9% on the broader mRNA platform validation.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/news/1182440965"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1182440965\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1182440965?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-19 21:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1182440965","market":"us","top_or_hot":-1,"title":"Movement Alert｜Moderna, Inc. Surges 85.9% in Regular Trading, Phase III mRNA Cancer Vaccine Trial Achieves Primary Endpoint","media":"Market Focus","content":"<p><p>On August 19, Moderna, Inc. surged 85.9% in regular trading, trading at $115.505/share, with turnover of $2.791 billion.</p><p>The surge was driven by Moderna and Merck jointly announcing that their pivotal Phase III clinical trial Interpath-001 achieved positive results. The trial evaluated intismeran autogene, a personalized neoantigen therapy, in combination with Keytruda for patients with completely resected stage IIB-IV melanoma. The combination demonstrated statistically significant and clinically meaningful improvements in both recurrence-free survival and distant metastasis-free survival compared with Keytruda alone, with no new safety signals identified.</p><p>This marks the first Phase III trial success for mRNA technology in oncology, representing a major milestone for personalized immunotherapy. The two companies stated they plan to engage regulatory authorities regarding submission of the combination therapy. William Blair subsequently upgraded Moderna to Outperform. Merck shares rose over 7%, while sector peer BioNTech gained 18.9% on the broader mRNA platform validation.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Moderna, Inc. Surges 85.9% in Regular Trading, Phase III mRNA Cancer Vaccine Trial Achieves Primary Endpoint</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Moderna, Inc. Surges 85.9% in Regular Trading, Phase III mRNA Cancer Vaccine Trial Achieves Primary Endpoint\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-08-19 21:31</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On August 19, Moderna, Inc. surged 85.9% in regular trading, trading at $115.505/share, with turnover of $2.791 billion.</p><p>The surge was driven by Moderna and Merck jointly announcing that their pivotal Phase III clinical trial Interpath-001 achieved positive results. The trial evaluated intismeran autogene, a personalized neoantigen therapy, in combination with Keytruda for patients with completely resected stage IIB-IV melanoma. The combination demonstrated statistically significant and clinically meaningful improvements in both recurrence-free survival and distant metastasis-free survival compared with Keytruda alone, with no new safety signals identified.</p><p>This marks the first Phase III trial success for mRNA technology in oncology, representing a major milestone for personalized immunotherapy. The two companies stated they plan to engage regulatory authorities regarding submission of the combination therapy. William Blair subsequently upgraded Moderna to Outperform. Merck shares rose over 7%, while sector peer BioNTech gained 18.9% on the broader mRNA platform validation.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MRNA","symbol_name":"Moderna, Inc.","start_time":0,"source_url":"","article_id":"1182440965","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1182440965","pubTimestamp":1787146267,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On August 19, Moderna, Inc. surged 85.9% in regular trading, trading at $115.505/share, with turnover of $2.791 billion.The surge was driven by Moderna and Merck jointly announcing that their pivotal...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MRNA":"Moderna, Inc."},"translate_title":"动态警报|Moderna, Inc. 常规交易飙升 85.9%，III 期 mRNA 癌症疫苗试验达到主要终点","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MRNA":1},"content_text":"On August 19, Moderna, Inc. surged 85.9% in regular trading, trading at $115.505/share, with turnover of $2.791 billion.The surge was driven by Moderna and Merck jointly announcing that their pivotal Phase III clinical trial Interpath-001 achieved positive results. The trial evaluated intismeran autogene, a personalized neoantigen therapy, in combination with Keytruda for patients with completely resected stage IIB-IV melanoma. The combination demonstrated statistically significant and clinically meaningful improvements in both recurrence-free survival and distant metastasis-free survival compared with Keytruda alone, with no new safety signals identified.This marks the first Phase III trial success for mRNA technology in oncology, representing a major milestone for personalized immunotherapy. The two companies stated they plan to engage regulatory authorities regarding submission of the combination therapy. William Blair subsequently upgraded Moderna to Outperform. Merck shares rose over 7%, while sector peer BioNTech gained 18.9% on the broader mRNA platform validation.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}